Technical Analysis for PTLA - Portola Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 20.0 -0.99% -0.20
PTLA closed down 0.99 percent on Friday, November 16, 2018, on 80 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical PTLA trend table...

Date Alert Name Type % Chg
Nov 16 20 DMA Resistance Bearish 0.00%
Nov 16 Calm After Storm Range Contraction 0.00%
Nov 16 NR7 Range Contraction 0.00%
Nov 15 20 DMA Resistance Bearish -0.99%
Nov 15 Multiple of Ten Bullish Other -0.99%
Nov 14 New Downtrend Bearish 4.28%
Nov 14 Multiple of Ten Bearish Other 4.28%
Nov 14 Down 3 Days in a Row Weakness 4.28%
Nov 14 Down 4 Days in a Row Weakness 4.28%
Nov 13 20 DMA Resistance Bearish -0.40%

Older signals for PTLA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Portola Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of thrombosis, other hematologic disorders, and inflammation. Its development products include Betrixaban, an oral once-daily inhibitor of Factor Xa, which is in Phase III development trials for the treatment of venous thromboembolism prophylaxis in acute medically ill patients; and PRT4445, a recombinant protein that is in Phase II trials to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. The company's products under development also comprise PRT2070, which is in Phase I/II studies to treat B-cell hematologic cancers; and PRT2607 that is in Phase I clinical trials for inflammatory disorders. It has a license and collaboration agreement with Biogen Idec Inc. for the development and commercialization of its clinical-stage product candidates PRT2607; license and collaboration agreement with Aciex Therapeutics, Inc. to co-develop and co-commercialize PRT2070 and related compounds for nonsystemic indications; and an agreement with Astellas Pharma, Inc. to research, develop, and commercialize Syk inhibitors. The company was founded in 2003 and is headquartered in South San Francisco, California.
Is PTLA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 56.7
52 Week Low 18.18
Average Volume 1,428,903
200-Day Moving Average 33.8589
50-Day Moving Average 23.6084
20-Day Moving Average 20.1215
10-Day Moving Average 20.21
Average True Range 1.5987
ADX 28.5
+DI 22.9318
-DI 25.2879
Chandelier Exit (Long, 3 ATRs ) 20.2039
Chandelier Exit (Short, 3 ATRs ) 22.9761
Upper Bollinger Band 22.2125
Lower Bollinger Band 18.0305
Percent B (%b) 0.47
BandWidth 20.783739
MACD Line -0.9302
MACD Signal Line -1.1672
MACD Histogram 0.237
Fundamentals Value
Market Cap 1.15 Billion
Num Shares 57.6 Million
EPS -4.55
Price-to-Earnings (P/E) Ratio -4.40
Price-to-Sales 85.78
Price-to-Book 24.64
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.91
Resistance 3 (R3) 21.87 21.19 21.59
Resistance 2 (R2) 21.19 20.71 21.21 21.48
Resistance 1 (R1) 20.60 20.41 20.90 20.64 21.38
Pivot Point 19.92 19.92 20.07 19.94 19.92
Support 1 (S1) 19.33 19.44 19.63 19.37 18.62
Support 2 (S2) 18.65 19.14 18.67 18.52
Support 3 (S3) 18.06 18.65 18.41
Support 4 (S4) 18.10